Making the step from academia into industry can seem daunting and can appear to require a very different skill set. Flavia Scialpi, Head of Biology at Synpromics, discusses how she used her experiences to make this transition in a recent blog post for Nature Jobs. Click here to read the article in full and learn more about Flavia’s career path and how setbacks may in fact be opportunities in disguise.
In April, Synpromics attended the 6th annual Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day in New York, a full-day conference featuring discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field’s most promising companies. Whilst there, David Venables, CEO of Synpromics, presented to potential investors and fellow biotech professionals.
Edinburgh, UK, 23rd April 2018 / Synpromics Ltd, the leader in gene control, announces a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals. The 18-month project has been made possible through the award of a £235,000 grant, part of the medicines manufacturing competition from Innovate UK.
As product developers move toward 2nd generation gene and cell medicine constructs, the importance of novel gene regulation and promoter elements has emerged. Synpromics is pleased to invite you to join them for a special symposium during the ASGCT Annual Meeting which will include presentations from Synpromics’ partners, an interactive panel discussion, and will be followed by a networking reception and refreshments. Please see the full agenda below.